Hyperandrogenism in Dermatology: Pathogenesis, Diagnosis, and Therapeutic Strategies



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In recent years, special attention has been paid to studying the etiopathogenetic features of hyperandrogenic conditions in women, which is due to their relevance and significance in modern dermatology. Increased levels of androgens are accompanied by a number of skin changes, such as androgenetic alopecia, acne, and hirsutism, which significantly affect the quality of life of patients. These manifestations not only cause physical discomfort, but also often lead to reproductive dysfunction, psychoemotional disorders, and a deterioration in overall well-being and social adaptation. Currently, the treatment of women with symptoms of hyperandrogenism is a challenging task, as there is no separate set of medical guidelines dedicated exclusively to hyperandrogenism, which makes a standardized approach to treatment difficult. The novelty of this review lies in the systematic compilation of current data on the pathogenesis, clinical manifestations, diagnosis, and treatment of hyperandrogenic conditions in women.

Full Text

Restricted Access

About the authors

Alina Zybareva

ФГБОУ ВО «Российский университет медицины», МЗ РФ, Москва

Author for correspondence.
Email: alinaziba@mail.ru
ORCID iD: 0000-0003-1259-5454

Аспирант кафедры кожных и венерических болезней

Russian Federation

Yuri Perlamutrov

Russian University of Medicine, Ministry of Health of the Russian Federation

Email: mgmsu-skin@mail.ru
ORCID iD: 0000-0002-4837-8489
SPIN-code: 2330-2758

Doctor of Medical Sciences, Professor, Head Department of Skin and Venereal Diseases

Russian Federation, Moscow, 4 Dolgorukovskaya Street

Dina Klyuchnikova

Russian University of Medicine, Ministry of Health of the Russian Federation

Email: dina_kl@list.ru
ORCID iD: 0000-0001-6595-1825
SPIN-code: 1809-7581

Candidate of Medical Sciences, Assistant Professor of the Department of Skin and Venereal Diseases

Russian Federation, Moscow, 4 Dolgorukovskaya Street

References

  1. Игумнов И., Шарифулин Э., Беленкая Л. В., Лазарева Л. М., Аталян А. В., Вилсон Н. И., Сутурина Л. В. Хроническое системное воспаление в путях метаболического синдрома, связанного с гиперандрогенизмом (обзор). doi: 10.25557/2310-0435.2020.03.12-18 // Nauchno-prakticheskii zhurnal «Patogenez», 2020
  2. Можейко Л.Ф., Потоцкая А.А. Синдром поликистозных яичников: современные подходы к проблеме (обзор литературы). doi: 10.34883/pi.2022.12.3.010 // Репродуктивное здоровье Восточная Европа, 2022
  3. Грязева Н.В., Тамразова А.В., Александрова Е.Б. Гормоны как дополнительная терапевтическая мишень в лечении акне doi: 10.26269/k15e-vj12 // Кремлевская медицина. Клинический вестник, 2022
  4. Бакиржан М.А., Кожемжарова М.К., Куанышбаева Г.С., Досжанова Г.Н., Каркабаева А.Д. Клинический случай гиперандрогении у пациентки с болезнью Иценко-Кушинга. doi: 10.37800/rm.1.2024.131-137 // Репродуктивная медицина, 2024
  5. Таганов А. В., Тихомиров Т. А., Рождественская О. А., Заславский Д. В., Тамразова О. Б., Гуреева М. А. Ожирение как фактор, способствующий патогенезу кожных заболеваний. doi: 10.33029/2304-9529-2021-10-4-52-61 // Endocrinology News Opinions Training, 2021
  6. Тeede H.J., Misso M.L., Costello M.F. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018;110(3):364–379. DOI: 10.1016/j. fertnstert.2018.05.004
  7. Angelica Lindén Hirschberg , Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman, The Journal of Clinical Endocrinology & Metabolism, Volume 108, Issue 5, May 2023, Pages 1243–1253, https://doi.org/10.1210/clinem/dgac673
  8. Xing C, Zhang J, Zhao H, He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int J Womens Health. 2022; 14(February 2):91-105
  9. H.Chaudhary, J. Patel The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis September 2021Journal of Ovarian Research 14(1):125 doi: 10.1186/s13048-021-00879-w
  10. S. F. S. Tabatabaie Association between IL-6 -174 G/C (rs1800795) and IL-1A -889 C/T (rs1800587) cytokine variants with polycystic ovary syndrome in Iranian women: A case-control study, Gene,V. 933, 15/01/2025, https://doi.org/10.1016/j.gene.2024.148906
  11. Eser B, Islimye Taskin M, Hismiogullari AA, Aksit H, Bodur AS. The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome. J Obstet Gynaecol. 2017 Apr;37(3):358-362. doi: 10.1080/01443615.2016.1256966. Epub 2016 Dec 26. PMID: 28019133
  12. Meczekalski B, Szeliga A, Maciejewska-Jeske M, Podfigurna A, Cornetti P, Bala G, Adashi EY. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol. 2021 Aug;37(8):677-682. doi: 10.1080/09513590.2021.1903419.
  13. Brown RJ, Joseph J, Cochran E, et al. Type B insulin resistance masquerading as ovarian hyperthecosis. J Clin Endocrinol Metab. 2017;102(6):1789-1791]
  14. Liu Y, Yao ZX, Papadopoulos V. Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells. Mol Endocrinol. 2005 Jul;19(7):1918-31. doi: 10.1210/me.2004-027
  15. Hammond GL. Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. J Endocrinol. 2016 Jul;230(1):R13-25. doi: 10.1530/JOE-16-0070. Epub 2016 Apr 25
  16. Li T, Mo H, Chen W, Li L, Xiao Y, Zhang J, Li X, Lu Y. Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome. Reprod Sci. 2017 May;24(5):646-655. doi: 10.1177/1933719116667606].
  17. Дедов И. И., Мельниченко Г. А., ред. Эндокринология. Национальное руководство. М.: ГЕОТАРМедиа; 2016. 1142 с. [Dedov I. I., Mel'nichenko G. A., red. Endokrinologiya. Natsional'noe rukovodstvo. M.: GEOTARMedia; 2016. 1142
  18. Burdea L, Sharma L, Mendez MD. 21-Hydroxylase Deficiency. 2025 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan
  19. Arnaldi G, Martino M. Androgens in Cushing's Syndrome. Front Horm Res. 2019;53:77-91. doi: 10.1159/000494904. Epub 2019 Sep 9
  20. Torchen, L. C., Wu, M., Thompson, B., & Beaudouin, A. (2025). Polycystic ovary syndrome: origins and implications: The significance of functional adrenal hyperandrogenism in polycystic ovary syndrome across the lifespan. Reproduction, 169(6), e250091. Retrieved Aug 1, 2025, from https://doi.org/10.1530/REP-25-0091
  21. Bendarska-Czerwińska A, Zmarzły N, Morawiec E, Panfil A, Bryś K, Czarniecka J, Ostenda A, Dziobek K, Sagan D, Boroń D, Michalski P, Pallazo-Michalska V, Grabarek BO. Endocrine disorders and fertility and pregnancy: An update. Front Endocrinol (Lausanne). 2023 Jan 17;13:970439. doi: 10.3389/fendo.2022.970439.
  22. Rojewska, B. Meczekalski, G. Bala, S. Luisi, and A. Podfigurna, “From Diagnosis to Treatment of Androgen-Secreting Ovarian Tumors: A Practical Approach,” Gynecological Endocrinology 38, no. 7 (2022): 537–542
  23. Kalfoutzou A, Petroulakis P, Mylonakis A, Restemi A, Chaleplidis N, Anagnou E, Tsikalakis G, Tsantopoulos M, Mostratou E (2025) Adrenocortical carcinoma with dual androgen and cortisol secretion. Folia Medica 67(1): e130505. https://doi.org/10.3897/folmed.67.e130505
  24. Wei-bin Zhou, Nan Chen, Cheng-jiang Li. A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman BMC Endocrine Disorders(2019) 19:14 doi.org/10.1186/s12902-019-0342-y
  25. Sharma A, Welt CK. Practical Approach to Hyperandrogenism in Women. Med Clin North Am. 2021 Nov;105(6):1099-1116. doi: 10.1016/j.mcna.2021.06.008. Epub 2021 Sep 8. PMID: 34688417; PMCID: PMC8548673.
  26. Цаллагова Е.В., Генералов В.О., Садыков Т.Р. Гиперандрогения как механизм развития побочных эффектов противосудорожных препаратов. Эпилепсия и пароксизмальные состояния. 2018; 10 (2): 43-50. doi: 10.17749/2077-8333.2018.10.2.043-050
  27. J. Kotzé, A. Richardson, Looking «acceptably» feminine: A single case study of a female bodybuilder’s use of steroids,Performance Enhancement & Health, Volume 8, Issues 2–3,2020,100174, https://doi.org/10.1016/j.peh.2020.100174.
  28. Shamseddin M, De Martino F, Constantin C, Scabia V, Lancelot AS, Laszlo C, Ayyannan A, Battista L, Raffoul W, Gailloud-Matthieu MC, Bucher P, Fiche M, Ambrosini G, Sflomos G, Brisken C. Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation. EMBO Mol Med. 2021 Jul 7;13(7):e14314. doi: 10.15252/emmm.202114314.
  29. A. Ciarloni, N. delli Muti et all Contribution of Androgen Receptor CAG Repeat Polymorphism to Human Reproduction, DNA 2025, 5(1), 9; https://doi.org/10.3390/dna5010009]. [Polat, S.; Karaburgu, S.; Unluhizarci, K.; Dündar, M.; Özkul, Y.; Arslan, Y.K.; Karaca, Z.; Kelestimur, F. The Role of Androgen Receptor CAG Repeat Polymorphism in Androgen Excess Disorder and Idiopathic Hirsutism. J. Endocrinol. Investig. 2020, 43, 1271–1281.
  30. Weintrob N, Eyal O, Slakman M, Segev Becker A, Ish-Shalom M, Israeli G, et al. (2018) The effect of CAG repeats length on differences in hirsutism among healthy Israeli women of different ethnicities. PLoS ONE 13(8): e0203181. https://doi.org/10.1371/journal.pone.0203181
  31. Arning, L., Ocklenburg, S., Schulz, S. et al. Handedness and the X chromosome: The role of androgen receptor CAG-repeat length. Sci Rep 5, 8325 (2015). https://doi.org/10.1038/srep08325
  32. Nehal M. Zuelfakkar, Nader F. Ragab, Abeer Shehab, Moemena Nagy. The association of cytosine-adenine-guanine repeat polymorphism in the androgen receptor gene with nodulocystic acne in Egyptian patients// DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20231823// International Journal of Research in Dermatology, 2023
  33. Khan, A.F.; Karami, S.; Peidl, A.S.; Waiters, K.D.; Babajide, M.F.; Bawa-Khalfe, T. Androgen Receptor in Hormone Receptor-Positive Breast Cancer. Int. J. Mol. Sci. 2023, 25, 476.
  34. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 Oct;37(5):467-520. doi: 10.1210/er.2015-1104. Epub 2016 Jul 26.
  35. Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018 Jun 19;4(4):203-211. doi: 10.1016/j.ijwd.2018.05.001
  36. Chan L, Cook DK. Female pattern hair loss. Aust J Gen Pract. 2018 Jul;47(7):459-464. doi: 10.31128/AJGP-02-18-4498.
  37. Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019 Jun;80(6):1497-1506. doi: 10.1016/j.jaad.2018.08.062
  38. Kasumagic-Halilovic E. Trichoscopic Findings in Androgenetic Alopecia. Med Arch. 2021 Apr;75(2):109-111. doi: 10.5455/medarh.2021.75.109-111
  39. Lewin Z, Vitek WS, O'Malley W, Astapova O. Resolution of Hyperandrogenism, Insulin Resistance and Acanthosis Nigricans (HAIR-AN) Syndrome After Sleeve Gastrectomy. JCEM Case Rep. 2023 Jan 17;1(1):luac030. doi: 10.1210/jcemcr/luac030. PMID: 37908254; PMCID: PMC10578405
  40. Adalsteinsson JA, Kaushik S, Muzumdar S, Guttman-Yassky E, Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020; 29: 481–489. https://doi.org/10.1111/exd.14091
  41. Л.А. Юсупова Себорейный дерматит: патогенетические аспекты, клинические формы и терапия больных.// Лечащий врач, 2019// doi: 10.26295/OS.2019.25.32.009
  42. Donbaloğlu Z, Tuhan H, Çoban ÖG, Kızılay DÖ, İsmailoğlu E, Önder A, Acar S, Bedel A, Çetiner EB, Singin B, Erdem H, Parlak M. Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome. Clin Pediatr Endocrinol. 2022;31(2):68-76. doi: 10.1297/cpe.2022-0010. Epub 2022 Mar 19.
  43. http://disuria.ru/load/zakonodatelstvo/klinicheskie_rekomendacii_protokoly_lechenija/54]
  44. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
  45. Teede HJ, Tay CT, Laven JJE et all International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023 Aug 2;189(2):G43-G64. doi: 10.1093/ejendo/lvad096
  46. Н.Г. Мокрышева, Г.А. Мельниченко, Л.В. Адамян и др. Врожденная дисфункция коры надпочечников (адреногенитальный синдром) (2021) 09/02/2024 "Клинические рекомендации" Министерство здравоохранения Российской Федерации Российская ассоциация эндокринологов
  47. Иловайская И.А. Гиперандрогенные нарушения и заболевания женщин: дифференциальная диагностика и лечебная тактика // doi: 10.31550/1727-2378-2018-150-6-49-55// Гинекология Эндокринология, 2018
  48. C. Bernárdez, A.M. Molina-Ruiz, L. Requena, Histologic Features of Alopecias–Part I: Nonscarring Alopecias, Actas Dermo-Sifiliográficas (English Edition),V. 106, Issue 3, 2015,P. 158-167, https://doi.org/10.1016/j.adengl.2015.01.001
  49. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. J Clin Med. 2023 Feb 11;12(4):1454. doi: 10.3390/jcm12041454.
  50. Чернуха Г.Е., Мирошина Е.Д., Кузнецов С.Ю., Иванов И.А. Индекс массы тела, композиционный состав тела и метаболический профиль пациенток с синдромом поликистозных яичников. Акушерство и гинекология. 2021; 10: 103-111 https://dx.doi.org/10.18565/aig.2021.10.103-111
  51. Grandi, G., Del Savio, M. C., & Facchinetti, F. (2021). The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism. Expert Review of Clinical Pharmacology, 14(2), 211–224. https://doi.org/10.1080/17512433.2021.1878876
  52. Bahaeldein E, Brassill MJ. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women. Endocrinol Diabetes Metab Case Rep. 2018;2018:18-0084. doi: 10.1530/EDM-18-0084
  53. Amiri M, Ramezani Tehrani F, Nahidi F, Kabir A, Azizi F. Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis. JMIR Res Protoc. 2018 Apr 25;7(4):e113. doi: 10.2196/resprot.9024

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.